Identification of a variant in NLRP3 gene in a patient with Muckle-Wells syndrome: a case report and review of literature.

Background

Cryopyrin-associated periodic syndrome (CAPS) is a rare genetic autoimmune disease with clinical heterogeneity. CAPS includes mild, moderate, and severe phenotypes. The mild phenotype is known as familial cold autoinflammatory syndrome (FCAs), the moderate phenotype is known as Muckle-Wells syndrome (MWS), and the severe phenotype is known as neonatal onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurocutaneous joint syndrome [ 1 , 2 ].

CAPS is caused by variations in the NLRP3 gene, which encodes cryopyrin, a key protein component of inflammasomes. These variations can lead to excessive production of interleukin-1β (IL-1β) which can lead to the occurrence of inflammatory reaction.

Here we reported a case of MWS, who had recurrent fever, urticarial-like rash, and bilateral conjunctival congestion. Whole exome sequencing identified a missense variation c.784-786delinsTGG (p.R262W) in the coding region of the NLRP3 gene. This gene variation site was the first to be reported in China.

Case presentation

A 3-year-old boy was first referred to our department in 2020 with complaints of recurrent fever with no apparent cause for more than 10 months. Each episode of fever generally lasted for about 1–5 days, and the interval between each episode was approximately 15 days. During all episodes of fever, the temperature was about 37.5ºC with occasional blips up to 39ºC, accompanied by bilateral conjunctival congestion and urticarial-like rash. There were no fatigue, headache, nasal congestion, runny nose, sore throat, cough and asthma, abdominal pain, vomiting and diarrhea, and joint swelling and pain. Routine blood examination showed elevation in leukocyte count, neutrophil count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) and serum amyloid protein (SAA) levels.

Whole exome sequencing identified a heterozygous variation of NLRP3 gene (c.784-786delinsTGG) in the coding region that resulted in amino acid substitution of arginine for tryptophan at codon 262 (p.R262W), which is a missense variation. The frequency of variation in this database is normal. Through family verification analysis, the parents of the subject had no variation at nucleotide locus 784 in the coding region, suggesting a spontaneous mutation. According to the ACMG guidelines, this mutation was preliminarily determined to be pathogenic. Furthermore, we verified the gene function through two software, and the results are as follows: 1. This variation is predicted to be probably damaging with a score of 1.000 by PolyPhen-2. 2. This variation is predicted to be disease causing with a score of 0.999 by MutationTaster. The mutation was validated using Sanger sequencing (Fig. 1 ). Fig.1 Sanger sequencing of NLRP3 gene in patient and his parents. a The position of the variant in NLRP3 gene in the patient. b The father of the patient has no variation at this locus. c The mother of the patient has no variation at this locus

According to clinical manifestation, laboratory examination results, and sequencing results, the boy was diagnosed with Muckle-Wells syndrome. He was subsequently treated with oral thalidomide at 12.5 mg, twice a day. During the medication period, there were no symptoms such as fever, rash, and conjunctivitis.

Discussion

Autoinflammatory disease (AUID) is caused by gene variations that change the protein encoded by them, leading to innate immune dysfunction and subsequent systemic excessive inflammatory response [ 3 ]. Most patients with AUID show sudden periodic fever, rash, serositis, lymphadenopathy, and arthritis. Inflammatory indexes generally increase during the attack period. However, during the asymptomatic interval, the growth and development of the patients are normal, as well as the inflammatory indexes. Among them, AUID caused by single gene variations are called monogenic autoinflflammatory diseases. Due to their genetic characteristics, the onset of this disease is early, and it can occur from newborn to adolescence [ 4 ]. With the development of gene sequencing technology, more than 50 monogenic autoinflflammatory diseases have been identified [ 5 ].

CAPS is an extremely rare continuum of autoinflammatory disease with severe and persistent inflammation status. This syndrome encompasses a spectrum of three subsets according to different clinical manifestation: FCAS, MWS and CINCA/ NOMID. CAPS was originally considered as three independent diseases. In fact, it is now considered as a disease process with different severity under the same genetic background. The clinical characteristics of CAPS was shown in Table 1 . In 1962, Muckle and Wells first described MWS with manifestations of urticaria rash, neurosensory hearing loss, and amyloidosis syndrome [ 6 ]. The typical clinical characteristics of MWS include: onset from infancy or early childhood, repeated intermittent fever without specific inducing factors (not closely related to cold exposure), accompanied by urticarial-like rash, joint pain, headache, conjunctivitis, etc., and the elevated systemic inflammatory indexes (leukocyte count, neutrophil count, CRP, SAA, ESR, etc.). The symptoms can last from 1 day to 2 weeks, and the interval between onset varies from a few weeks to several months. Sensorineural deafness can occur during adolescence, and 1/3 of patients will have AA-type amyloidosis, which can cause serious complications such as renal failure [ 7 ]. The main manifestations in this case were recurrent fever, urticarial-like rash, and conjunctivitis without obvious inducement, accompanied by elevated neutrophils, CRP, SAA, and ESR. After the administration of thalidomide, the symptoms were well controlled, and the laboratory indexes returned to normal. The MWS-DAS score of this case was less than 10 [ 8 , 9 ]. Considering that the disease activity was mild, long-term follow-up is needed in the future to pay attention to the occurrence of hearing damage, AA amyloidosis, and kidney damage. Table 1 Clinical characteristics of CAPS (adapted from [ 10 , 11 ]) FCAS MWS CINCA/NOMID Severity mild moderate severe Age at onset < 6 months-adulthood Early childhood-adulthood Perinatal Family history Often positive Often positive Often negative Triggers Generalized cold/pneumovax Stress/excercise/infection/pneumovax Stress/excercise/infection/pneumovax Cold trigger Yes Possible Rare Fever Yes Yes Yes Fatigue Rare Yes Yes Cutaneous manifestations Urticaria-like rash Urticaria-like rash Urticaria-like rash Ocular manifestations Conjunctivitis/keratitis Conjunctivitis/ketatitis/uveitis Conjunctivitis/ketatitis/uveitispapilledema Muskulosceletal manifestations Myalgia/arthralgia Myalgia/arthralgia/arthritis Myalgia/arthralgia/arthritis/distal femur overgrowth Central nervous system manifestations Headache Headache/intermittent aseptic meningitis Headache/sterile meingtitis/elevated intracranial pressure/brain atrophy Hearing loss No Yes Yes Amyloidosis Rare Yes Yes

CAPS is caused by dominantly inherited or de novo gain-of-function mutations in the NOD-like receptor 3 ( NLRP3 ) (also known as CIAS1 or NALP3 ) gene located on chromosome 1q44 [ 12 ]. The NLRP3 gene encodes the NLRP3 protein (cryopyrin), which can oligomerize and recruit other intracellular proteins such as ASC (apoptosis related spot like protein containing caspase recruitment domain) and several chaperones to form NLRP3 inflammasomes. The formation of this complex activates the proinflammatory protease called caspase-1, which in turn mediates release of proinflammatory cytokines such as IL-1β [ 13 – 16 ]. IL-1β can cause fever, vasodilation, and systemic inflammation. Therefore, NLRP3 gene variation can lead to continuous activation of inflammasomes and excessive production of IL-1, leading to systemic inflammation [ 17 , 18 ]. The incidence rate of CAPS in the United States is about 1/1,000,000 [ 19 ], and the estimated prevalence in France is 1/360,000 [ 20 ]. However, the incidence rate in China is still unknown. In 2012, the expert group developed a set of practice guidelines for hereditary recurrent fever (HRF), which pointed out some specific gene variation sites of CAPS (p.R260W, p.D303N, p.L305P, p.E311K, p.T348M, p.L353P, p.A439V, p.V198M, and p.Q703K) [ 21 ]. Infevers database ( https://infevers.umai-montpellier.fr/web/ ) listed more than 240 sequence variants of NLRP3 gene as of November 2020, and more than 100 are known to be pathogenic/possible pathogenic, and most of which are located in exon 3 [ 22 ]. In recent years, with deepened understanding of the diseases and widespread application of second-generation sequencing technology, many cases of CAPS have been reported in China [ 23 – 26 ]. The R260W (also known as R262W) variation of NLRP3 gene was first reported in 2002 and its involvement in MWS and FCU was confirmed, but some clinical symptoms, such as deafness, AA-type amyloidosis, and cold sensitivity, do not always exist, indicating that NLRP3 gene variation is not an independent pathogenic factor, and there may be epigenetic and other factors involved in the pathogenesis. Unknown gene modification may affect its phenotype [ 27 ]. Our sequencing results showed that there was a heterozygous variation in the NLRP3 gene, which led to the R > W missense variation at amino acid 262. Considering his pathogenesis, clinical and laboratory manifestations, he was diagnosed with MWS. Previous studies have found that MWS is common in the Nordic population. Our findings have expanded the ethnic scope and clinical manifestation spectrum of the disease. The variation site of R260W was reported for the first time in China.

It has been reported that the clinical phenotypes of MWS patients with the variation of R260W mainly include: symptoms after 6 months (median > 2 years), positive family history, cold trigger attack, and most of them have experienced chronic disease course [ 2 , 28 ]. This case showed symptoms at the age of 3 years and experienced a chronic course of disease, which seems to be inconsistent with previous literature reports. In combination with other MWS cases reported in China so far (Table 2 ), we found that the clinical manifestations of MWS cases in China were basically consistent with those reported abroad, but no renal amyloidosis has occurred so far, which may be related to the short follow-up time and small number of cases, and also not exclude the relationship with race, epigenetic and other factors. Table 2 Summary of the patients with MWS reported in China Patient Gender Age at onset (years) Family history Cold trigger Clinical characteristics Fever Skin rash Oral ulcer Conjunctivitis Myalgia Arthralgia/arthritis Abdominal pain Headache Hearing loss Chronic meningitis Renal amyloidosis 1 [[[ 23 ]]] Male 7 × × √ √ × × × √ × × × × × 2 [[[ 23 ]]] Male 46 × × √ √ √ × √ √ √ × × × × 3 [[[ 23 ]]] Male 2 × × √ √ √ √ √ × × √ × × × 4 [[[ 23 ]]] Male 2 × × √ √ √ √ × √ × √ √ √ × 5 [[[ 24 ]]] Male 7 × × √ √ × × × √ × × × × × 6 a Male 3 × × √ √ × √ × × × × × × × Patient Laboratory indicators NLRP3 variation Treatment Increased CRP Increased ESR Increased SAA Nucleotide exchange Amino acid exchange 1 [[[ 23 ]]] √ √ - c.86A > T p.D26V prednisone + MTX 2 [[[ 23 ]]] √ √ - c.2107C > A p.Q703K prednisone + TwHF 3 [[[ 23 ]]] √ √ - c.208G > A p.V70M prednisone 4 [[[ 23 ]]] √ √ - c.1043C > T p.T348M prednisone + CsA 5 [[[ 24 ]]] √ √ - c.92A > T p.D31V prednisone + MTX → colchicine → etanercept → × 6 a √ √ √ c.784-786delinsTGG p.R262W thalidomide a Case in this report

The objective of the treatment of CAPS is to inhibit systemic inflammation, prevent organ injury, and improve the quality of life of patients. Due to the central role of IL-1 in the pathogenesis of CAPS, biologically targeted therapy against IL-1 is recommended for CAPS [ 29 ]. At present, three IL-1 blockers consisting of anakina, canakinumab, and rilonacept are approved for CAPS. Anakinra is a short acting recombinant IL-1 receptor antagonist, which has been approved by the European Drug Administration (EMA) and the U.S. Food and Drug Administration (FDA). Canakinumab is an EMA and FDA approved fully humanized monoclonal antibody against IL-1, which can selectively bind soluble IL-1. Rilonacept is a soluble recombinant IL-1 receptor antagonist, which has only been approved by FDA. It is a pity that it is difficult to purchase IL-1 blockers from abroad due to COVID-19. And the domestic IL-1 blockers are still in the clinical trial stage. In addition, some non-steroidal anti-inflammatory drugs and immune modulators have been confirmed that they play a role in improving symptoms. Thalidomide was used to treat pregnancy vomiting in the 1950s, and was later stopped because of the deformity of newborn limbs [ 30 ]. Later, it was accidentally discovered that thalidomide can be used to treat leprosy erythematous nodules. Its anti-inflammatory, immunosuppressive and anti-tumor effects have gradually attracted widespread attention, and it is now used to treat multiple myeloma, leukemia, systemic lupus erythematosus, inflammatory bowel disease, Behcet's disease, adult still's disease and other diseases [ 31 , 32 ]. Furthermore, it has been reported that the clinical course of CAPS patient was improved during and after treatment with thalidomide [ 33 ].

The immunoregulatory effect of thalidomide is mainly manifested in the expression of some cytokines and adhesion molecules, as well as the regulation of immune cell activity: 1. Regulatory effect on cytokines. (1) Regulation of TNF-α: thalidomide can specifically reduce the level of TNF-a and regulate the secretion of other cytokines induced by TNF-α (such as IL-6, 8, 12, etc.). The regulation of thalidomide on TNF-α may be through the regulation of cytochrome C pathway, leading to apoptosis of monocytes, accelerating the degradation of TNF-α mRNA, thus leading to the decrease of TNF-α production, and thus affecting the inflammatory response [ 34 , 35 ]. (2) Regulation of IL: thalidomide can effectively inhibit the production of IL-1, 6 and 12, increase the production of IL-2, 4 and 10, and thus reduce inflammation. Thalidomide has a regulatory effect on lymphocytes, which is shown in that it can stimulate the proliferation of CTL cells and reduce the ratio of CD4 + /CD8 + . The effect of thalidomide on IL may be through changing the expression of ICAM-1 and LFA-1 on the surface of peripheral blood cells, affecting the interaction between cells, reducing the aggregation of lymphocytes to inflammatory sites, and thus regulating the production of IL [ 36 ]. It has also been found that thalidomide can play a role by inhibiting the expression of IL-6 receptor mRNA in a time and dose dependent manner [ 35 ]. 2. Inhibition of NF-κB. NF-κB is a key substance regulating inflammatory factor gene, and exists in the form of complex with inhibitor I-κB in the cytoplasm. It was found that thalidomide may selectively inhibit the activation of NF-κB mediated by inflammatory factors by acting on I-κB kinase, inactivate the expression of NF-κB, and then inhibit the expression of related inflammatory factors [ 37 ]. 3. Anti angiogenic effect: Thalidomide can significantly inhibit VEGF secretion and angiogenesis, increase cell apoptosis, and its anti angiogenesis effect may be related to the angiointegrin pathway [ 38 ]. Therefore, we finally chose thalidomide for empirical treatment in view of the light clinical performance of this patient, combined with the drug source, cost, treatment tolerance and potential side effects of IL-1 blocker. Interestingly, we found that the clinical manifestations and laboratory indicators of this case have been well controlled for 2 years after the empirical administration of thalidomide. At the same time, no side effects related to thalidomide have been found during the follow-up period. We speculated that this might be related to the mild condition of the case, but we also speculated whether it was also relevant to the gene variation of c.784-786delinsTGG (p.R262W), which needs to be further studied in the future. What is more important, close follow-up is still needed to regularly monitor the disease activity and evaluate organ damage in the future.

As we all know, fever is the most common clinical manifestation in children, and the causes are also diverse. Therefore, the diagnosis and differential diagnosis of fever in children is very challenging. Thus, clinically, children with recurrent fever, rash, musculoskeletal symptoms, and elevated inflammatory indicators, especially those with a positive family history, should be alert to the possibility of CAPS. If CAPS is suspected, the NLRP3 gene should be detected using molecular genetics for the presence of variations. If diagnosis is confirmed, the patients should be treated individually and closely followed up to prevent further organ damage and maximize the quality of life.

Conclusion

In this case, MWS was suspected and confirmed by the presence of a classical variation of the NLRP3 gene, which has also been reported in other MWS patients. This variation was reported in China for the first time. Our findings have expanded the ethnic scope and clinical manifestation spectrum of the disease, and equally important, provide a new idea for the diagnosis of recurrent fever. However, more in-depth follow-up and research are needed to optimize the treatment of MWS.

Abbreviations

Cryopyrin-associated periodic syndrome

Familial cold autoinflammatory syndrome

Muckle-Wells syndrome

Neonatal onset multisystem inflammatory disease

NOD-like receptor 3

Erythrocyte sedimentation rate

Erythrocyte sedimentation rate

Erythrocyte sedimentation rate

Interleukin-1β

Autoinflammatory disease

Hereditary recurrent fever

European drug administration

Food and drug administration

Methotrexate

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

Not applicable.

Authors' contributions

LJ: wrote the manuscript. LJ, ZRR and YZ: analysed data and retrieved bibliography. ZQY, CH and LY: reviewed the manuscript. LJ and ZQY: involved in medical diagnosis, management and follow up of the patient. All authors have read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

The study was approved by Ethics Committee of Affiliatied Hospital of Qingdao University. All methods were performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments or comparable ethical standards. A written informed consent was obtained from the patient’s parents. Include a statement on ethics approval and consent.

Consent for publication

All authors give consent for publication.

Competing interests

The authors declare no potential competing interests with respect to the research, authorship, and/or publication of this article.

References

1. Aksentijevich I Putnam CD Remmers EF Mueller JL Le J Kolodner RD The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model Arthritis Rheum 2007 56 4 1273 1285 10.1002/art.22491 17393462 PMC4321998

2. Levy R Gérard L Kuemmerle-Deschner J Lachmann HJ Koné-Paut I Cantarini L Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry Ann Rheum Dis 2015 74 11 2043 2049 10.1136/annrheumdis-2013-204991 25038238

3. Hull KM Drewe E Aksentijevich I Singh HK Wong K McDermott EM The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder Medicine 2002 81 5 349 368 10.1097/00005792-200209000-00002 12352631

4. Rigante D The fresco of autoinflammatory diseases from the pediatric perspective Autoimmun Rev 2012 11 5 348 356 10.1016/j.autrev.2011.10.008 22024500

5. Georgin-Lavialle S Ducharme-Benard S Sarrabay G Savey L Grateau G Hentgen V Systemic autoinflammatory diseases: Clinical state of the art Best Pract Res Clin Rheumatol 2020 34 4 101529 10.1016/j.berh.2020.101529 32546426

6. Muckle TJ Wellsm, Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome Q J Med 1962 31 235 48 14476827

7. Appels CW Kloppenburg M Muckle-Wells syndrome: a rare periodic fever syndrome Ned Tijdschr Geneeskd 2006 150 29 1628 1631 16901068

8. Kuemmerle-Deschner JB Tyrrell PN Koetter I Wittkowski H Bialkowski A Tzaribachev N Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome Arthritis Rheum 2011 63 3 840 849 10.1002/art.30149 21360513

9. Kümmerle-Deschner JB Tyrrell PN Reess F Kötter I Lohse P Girschick H Risk factors for severe Muckle-Wells syndrome Arthritis Rheum 2010 62 12 3783 3791 10.1002/art.27696 20722029

10. Booshehri LM Hoffman HM CAPS and NLRP3 J Clin Immunol 2019 39 3 277 286 10.1007/s10875-019-00638-z 31077002 PMC8575304

11. Welzel T Kuemmerle-Deschner JB Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today? J Clin Med 2021 1 10 1 10.3390/jcm10010128 PMC7794776 33401496

12. Hoffman HM Mueller JL Broide DH Wanderer AA Kolodner RD Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome Nat Genet 2001 29 3 301 305 10.1038/ng756 11687797 PMC4322000

13. Agostini L Martinon F Burns K McDermott MF Hawkins PN Tschopp J NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder Immunity 2004 20 3 319 325 10.1016/s1074-7613(04)00046-9 15030775

14. Martinon F Burns K Tschopp J The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta Mol Cell 2002 10 2 417 426 10.1016/s1097-2765(02)00599-3 12191486

15. Tran TAT Grievink HW Lipinska K Kluft C Burggraaf J Moerland M Whole blood assay as a model for in vitro evaluation of inflammasome activation and subsequent caspase-mediated interleukin-1 beta release PLoS One 2019 14 4 e0214999 10.1371/journal.pone.0214999 30958862 PMC6453527

16. Afonina IS Müller C Martin SJ Beyaert R Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme Immunity 2015 42 6 991 1004 10.1016/j.immuni.2015.06.003 26084020

17. Touitou I Koné-Paut I Autoinflammatory diseases Best Pract Res Clin Rheumatol 2008 22 5 811 829 10.1016/j.berh.2008.08.009 19028365

18. Tschopp J Martinon F Burns K NALPs: a novel protein family involved in inflammation Nat Rev Mol Cell Biol 2003 4 2 95 104 10.1038/nrm1019 12563287

19. Sarrabay G Grandemange S Touitou I Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts Expert Rev Clin Immunol 2015 11 7 827 835 10.1586/1744666x.2015.1047765 25979514

20. Cuisset L Jeru I Dumont B Fabre A Cochet E Le Bozec J Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France Ann Rheum Dis 2011 70 3 495 499 10.1136/ard.2010.138420 21109514

21. Shinar Y Obici L Aksentijevich I Bennetts B Austrup F Ceccherini I Guidelines for the genetic diagnosis of hereditary recurrent fevers Ann Rheum Dis 2012 71 10 1599 1605 10.1136/annrheumdis-2011-201271 22661645 PMC3500529

22. Sarrauste de Menthière C Terrière S Pugnère D Ruiz M Demaille J Touitou I INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003 1 31 282 5 10.1093/nar/gkg031 PMC165478 12520003

23. Wu D Shen M Muckle-Wells syndrome in Chinese patients: a single center case series Clin Rheumatol 2017 36 4 965 969 10.1007/s10067-016-3523-3 28028683

24. Gong Y Shen M Clinical features of autoinflammatory diseases in 3 patients Chin J Gen Pract 2014 13 10 832 834

25. Hu J Zhu Y Zhang J-Z Zhang R-G Li H-M A novel mutation in the pyrin domain of the NOD-like receptor family pyrin domain containing protein 3 in Muckle-Wells syndrome Chin Med J 2017 130 5 586 593 10.4103/0366-6999.200537 28229991 PMC5339933

26. Li C Tan X Zhang J Li S Mo W Han T Gene mutations and clinical phenotypes in 15 Chinese children with cryopyrin-associated periodic syndrome (CAPS) Science China Life Sciences 2017 60 12 1436 1444 10.1007/s11427-017-9246-4 29285715

27. Dodé C Le Dû N Cuisset L Letourneur F Berthelot JM Vaudour G New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes Am J Hum Genet 2002 70 6 1498 1506 10.1086/340786 11992256 PMC379138

28. Tran TA Muckle-Wells syndrome: clinical perspectives Open Access Rheumatol 2017 9 123 129 10.2147/oarrr.S114447 28744167 PMC5513904

29. Ter Haar NM Oswald M Jeyaratnam J Anton J Barron KS Brogan PA Recommendations for the management of autoinflammatory diseases Ann Rheum Dis 2015 74 9 1636 1644 10.1136/annrheumdis-2015-207546 26109736

30. Randall T Thalidomide has 37-year history JAMA 1990 263 11 1474 10.1001/jama.1990.03440110028006 2407870

31. Millrine D Kishimoto T A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders Trends Mol Med 2017 23 4 348 361 10.1016/j.molmed.2017.02.006 28285807

32. Mercurio A Adriani G Catalano A Carocci A Rao L Lentini G A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma Curr Med Chem 2017 24 25 2736 2744 10.2174/0929867324666170601074646 28571559

33. Kallinich T Hoffman HM Roth J Keitzer R The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide. Scand J Rheumatol. 2005 3 34 246 9 10.1080/03009740410010236 16134734

34. Alexandre-Moreira MS Takiya CM de Arruda LB Pascarelli B Gomez RN Castro Faria Neto HC LASSBio-468: a new achiral thalidomide analogue which modulates TNF-alpha and NO production and inhibits endotoxic shock and arthritis in an animal model. Int Immunopharmacol. 2005 3 5 485 94 10.1016/j.intimp.2004.10.017 15683845

35. Oliver SJ Freeman SL Corral LG Ocampo CJ Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis Clin Exp Immunol 1999 118 2 315 321 10.1046/j.1365-2249.1999.01039.x 10540197 PMC1905423

36. Singhal S Mehta J Desikan R Ayers D Roberson P Eddlemon P Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 1999 341 21 1565 1571 10.1056/nejm199911183412102 10564685

37. Yasui K Kobayashi N Yamazaki T Agematsu K Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation Curr Pharm Des 2005 11 3 395 401 10.2174/1381612053382179 15723633

38. McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis Med Hypotheses 1997 49 2 123 131 10.1016/s0306-9877(97)90217-6 9278924